Table Info

Table 1.

Summary of the properties and advantages of cell-derived vesicles

Platform	Properties	Advantages	Reference
Whole cell	Own the components and properties of cell, such as cell membrane, organelles, etc.	High loading capacity; Low immunogenicity; Good biocompatibility; Long circulation time.	[25, 33–35]
Cell-derived membranous structures	Participate in cell-to-cell communication; Cannot replicate like cells; Carry proteins, nucleic acids, lipids and other substances from mother cells.	Wide variety of sources; Excellent targeting ability.	[30, 45–47]

Declarations

Author contributions

Both authors contributed to the writing of the manuscript, and edited the manuscript at all stages. JX was responsible for collecting and writing the manuscript. CW was responsible for writing, reviewing and editing the manuscript.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by grants from startup supports of Soochow University and the Program for Jiangsu Specially-Appointed Professors to CW. This work was also supported by National Natural Science Foundation of China (No. 31900988, 32022043), the Natural Science Foundation of Jiangsu Province (No. SBK2019040088) and Jiangsu Province Six Talent Peaks Project (No. SWYY-110). This work was partly supported by Collaborative Innovation Center of Suzhou Nano Science & Technology, the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the 111 Project. The funders had a role in the design and preparation of the manuscript.

Copyright

References

Carr EJ, Dooley J, Garcia-Perez JE, Lagou V, Lee JC, Wouters C, et al. The cellular composition of the human immune system is shaped by age and cohabitation. Nat Immunol. 2016;17:461–8. [DOI] [PubMed] [PMC]

Irvine DJ. Materializing the future of vaccines and immunotherapy. Nat Rev Mater. 2016;1:15008. [DOI]

Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19:587–602. [DOI] [PubMed]

Klevorn LE, Teague RM. Adapting cancer immunotherapy models for the real world. Trends Immunol. 2016;37:354–63. [DOI] [PubMed] [PMC]

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273–90. [DOI] [PubMed] [PMC]

Zhang P, Zhai Y, Cai Y, Zhao Y, Li Y. Nanomedicine-based immunotherapy for the treatment of cancer metastasis. Adv Mater. 2019;31:e1904156. [DOI] [PubMed]

Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0182. [DOI] [PubMed] [PMC]

Yu W, He X, Yang Z, Yang X, Xiao W, Liu R, et al. Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis. Biomaterials. 2019;217:119309. [DOI] [PubMed]

Curran KJ, Silverman LB, Kobos R, Kernan NA, Margossian SP, Park JH, et al. Abstract IA07: chimeric antigen receptor T cells for cancer immunotherapy. AACR; 2016.76 Suppl:IA07. [DOI]

10.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61. [DOI] [PubMed] [PMC]

11.

Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566–81. [DOI] [PubMed] [PMC]

12.

Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19:5–18. [DOI] [PubMed]

13.

Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20:321–34. [DOI] [PubMed] [PMC]

14.

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas AJC. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23. [DOI] [PubMed] [PMC]

15.

Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182:655–71.e22. [DOI] [PubMed] [PMC]

16.

Singh B, Schwartz JA, Sandrock C, Bellemore SM, Nikoopour E. Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells. Indian J Med Res. 2013;138:591–4. [PubMed] [PMC]

17.

Shields CW, Wang LL, Evans MA, Mitragotri S. Materials forimmunotherapy. Adv Mater. 2020;32:e1901633. [DOI] [PubMed]

18.

Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Current perspectives in cancer immunotherapy. Cancers (Basel). 2019;11:1472. [DOI]

19.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175–96. [DOI] [PubMed] [PMC]

20.

Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater. 2019;4:398–414. [DOI]

21.

Xu X, Li T, Shen S, Wang J, Abdou P, Gu Z, et al. Advances in engineering cells for cancer immunotherapy. Theranostics. 2019;9:7889–905. [DOI] [PubMed] [PMC]

22.

Fan Q, Chen Z, Wang C, Liu Z. Toward biomaterials for enhancing immune checkpoint blockade therapy. Adv Funct Mater. 2018;28:1802540. [DOI]

23.

Cai L, Xu J, Yang Z, Tong R, Dong Z, Wang C, et al. Engineered biomaterials for cancer immunotherapy. MedComm. 2020;1:35–46. [DOI]

24.

Fan Q, Wang C. Engineering nanobiomaterials for cancer immunotherapy. Sci Sin Vitae. 2020;50. [DOI]

25.

Wang C, Wen D, Gu Z. Cellular bioparticulates with therapeutics for cancer immunotherapy. Bioconjug Chem. 2018;29:702–8. [DOI] [PubMed]

26.

Tian H, Li W. Dendritic cell-derived exosomes for cancer immunotherapy: hope and challenges. Ann Transl Med. 2017;5:221. [DOI] [PubMed] [PMC]

27.

Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang JE, et al. Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy. Mol Ther. 2020;28:536–47. [DOI] [PubMed] [PMC]

28.

Yan W, Jiang S. Immune cell-derived exosomes in the cancer-immunity cycle. Trends Cancer. 2020;6:506–17. [DOI] [PubMed]

29.

Di Pace AL, Tumino N, Besi F, Alicata C, Conti LA, Munari E, et al. Characterization of human NK cell-derived exosomes: role of DNAM1 receptor in exosome-mediated cytotoxicity against tumor. Cancers (Basel). 2020;12:661. [DOI]

30.

Kato T, Fahrmann JF, Hanash SM, Vykoukal J. Extracellular vesicles mediate B cell immune response and are a potential target for cancer therapy. Cells. 2020;9:1518. [DOI]

31.

Ma Q, Fan Q, Xu J, Bai J, Han X, Dong Z, et al. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles. Matter. 2020;3:287–301. [DOI] [PubMed] [PMC]

32.

Hamidi M, Tajerzadeh H. Carrier erythrocytes: an overview. Drug Deliv. 2003;10:9–20. [DOI] [PubMed]

33.

Gao M, Liang C, Song X, Chen Q, Jin Q, Wang C, et al. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv Mater. 2017;[Epub ahead of print]. [DOI]

34.

Yan J, Yu J, Wang C, Gu Z. Red blood cells for drug delivery. Small Methods. 2017;1. [DOI]

35.

Pishesha N, Bilate AM, Wibowo MC, Huang NJ, Li Z, Deshycka R, et al. Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A. 2017;114:3157–62. [DOI] [PubMed] [PMC]

36.

Han X, Shen S, Fan Q, Chen G, Archibong E, Dotti G, et al. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. 2019;5:eaaw6870. [DOI]

37.

Han X, Wang C, Liu Z. Red blood cells as smart delivery systems. Bioconjug Chem. 2018;29:852–60. [DOI] [PubMed]

38.

Zou MZ, Liu WL, Gao F, Bai XF, Chen HS, Zeng X, et al. Artificial natural killer cells for specific tumor inhibition and renegade macrophage re-education. Adv Mater. 2019;31:e1904495. [DOI] [PubMed]

39.

Schafer C, Ascui G, Ribeiro CH, Lopez M, Prados-Rosales R, Gonzalez PA, et al. Innate immune cells for immunotherapy of autoimmune and cancer disorders. Int Rev Immunol. 2017;36:315–37. [DOI] [PubMed]

40.

Wang H, Mooney DJ. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat Mater. 2018;17:761–72. [DOI] [PubMed]

41.

Lee DA. Cellular therapy: adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019;290:85–99. [DOI] [PubMed]

42.

Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200–18. [DOI] [PubMed]

43.

Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016;34:1330–8. [DOI] [PubMed]

44.

Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14:195–208. [DOI] [PubMed] [PMC]

45.

Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine. 2013;44:11–9. [DOI] [PubMed] [PMC]

46.

Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30:836–48. [DOI] [PubMed] [PMC]

47.

Mathieu M, Martin-Jaular L, Lavieu G, Thery C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21:9–17. [DOI] [PubMed]

48.

Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373–83. [DOI] [PubMed] [PMC]

49.

Susa F, Limongi T, Dumontel B, Vighetto V, Cauda V. Engineered extracellular vesicles as a reliable tool in cancer nanomedicine. Cancers (Basel). 2019;11:1979. [DOI]

50.

Pasini L, Ulivi P. Extracellular vesicles in non-small-cell lung cancer: functional role and involvement in resistance to targeted treatment and immunotherapy. Cancers (Basel). 2019;12:40. [DOI]

51.

Maacha S, Bhat AA, Jimenez L, Raza A, Haris M, Uddin S, et al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol Cancer. 2019;18:55. [DOI] [PubMed] [PMC]

52.

Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun. 2019;10:3000. [DOI] [PubMed] [PMC]

53.

Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer-implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018;15:617–38. [DOI] [PubMed]

54.

Katsuda T, Kosaka N, Ochiya T. The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers. Proteomics. 2014;14:412–25. [DOI] [PubMed]

55.

Tominaga N, Yoshioka Y, Ochiya T. A novel platform for cancer therapy using extracellular vesicles. Adv Drug Deliv Rev. 2015;95:50–5. [DOI] [PubMed]

56.

Al-Shura AN. Advanced hematology in integrated cardiovascular chinese medicine. Amsterdam: elsevier; 2020.

57.

Paolillo M, Schinelli S. Integrins and exosomes, a dangerous liaison in cancer progression. Cancers (Basel). 2017;9:95. [DOI]

58.

Yan J, Liu B, Shi Y, Qi H. Class II MHC-independent suppressive adhesion of dendritic cells by regulatory T cells in vivo. J Exp Med. 2017;214:319–26. [DOI] [PubMed] [PMC]

59.

Tung SL, Boardman DA, Sen M, Letizia M, Peng Q, Cianci N, et al. Regulatory T cell-derived extracellular vesicles modify dendritic cell function. Sci Rep. 2018;8:6065. [DOI] [PubMed] [PMC]

60.

Yang J, Dang G, Lu S, Liu H, Ma X, Han L, et al. T-cell-derived extracellular vesicles regulate B-cell IgG production via pyruvate kinase muscle isozyme 2. FASEB J. 2019;33:12780–99. [DOI] [PubMed] [PMC]

61.

Lu J, Wu J, Xie F, Tian J, Tang X, Guo H, et al. CD4⁺ T cell-released extracellular vesicles potentiate the efficacy of the HBsAg vaccine by enhancing B cell responses. Adv Sci (Weinh). 2019;6:1802219. [DOI] [PubMed] [PMC]

62.

Zhang F, Li R, Yang Y, Shi C, Shen Y, Lu C, et al. Specific decrease in B-cell-derived extracellular vesicles enhances post-chemotherapeutic CD8⁺ T cell responses. Immunity. 2019;50:738–50.e7. [DOI] [PubMed]

63.

Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. 2019;40:310–27. [DOI]

64.

Tang PMK, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144–58. [DOI] [PubMed]

65.

Liu R, An Y, Jia W, Wang Y, Wu Y, Zhen Y, et al. Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer. J Control Release. 2020;321:589–601. [DOI] [PubMed]

66.

Hu C, Lei T, Wang Y, Cao J, Yang X, Qin L, et al. Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity. Biomaterials. 2020;255:120159. [DOI] [PubMed]

67.

Zhou J, Li X, Wu X, Zhang T, Zhu Q, Wang X, et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol Res. 2018;6:1578–92. [DOI] [PubMed]

68.

Rayamajhi S, Nguyen TDT, Marasini R, Aryal S. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 2019;94:482–94. [DOI] [PubMed]

69.

Fang RH, Kroll AV, Zhang LJ. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy. Small. 2015;11:5483–96. [DOI] [PubMed] [PMC]

70.

Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24. [DOI] [PubMed]

71.

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5:e1071008. [DOI] [PubMed] [PMC]

72.

Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016;113:E968–77. [DOI] [PubMed] [PMC]

73.

Lindenbergh MFS, Koerhuis DGJ, Borg EGF, van’t Veld EM, Driedonks TAP, Wubbolts R, et al. Bystander T-cells support clonal T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles. Front Immunol. 2019;10:448. [DOI] [PubMed] [PMC]

74.

Tkach M, Kowal J, Zucchetti AE, Enserink L, Jouve M, Lankar D, et al. Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes. EMBO J. 2017;36:3012–28. [DOI] [PubMed] [PMC]

75.

Larssen P, Veerman RE, Akpinar GG, Hiltbrunner S, Karlsson MCI, Gabrielsson S. Allogenicity boosts extracellular vesicle-Induced antigen-specific immunity and mediates tumor protection and long-term memory in vivo. J Immunol. 2019;203:825–34. [DOI] [PubMed]

76.

Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16:431–46. [DOI] [PubMed]

77.

Hernández JCC, Bracko O, Kersbergen CJ, Muse V, Haft-Javaherian M, Berg M, et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models. Nat Neurosci. 2019;22:413–20 [DOI] [PubMed] [PMC]

78.

Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159–75. [DOI] [PubMed]

79.

Xue J, Zhao Z, Zhang L, Xue L, Shen S, Wen Y, et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol. 2017;12:692–700. [DOI] [PubMed]

80.

Gao J, Wang S, Wang Z. High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy. Biomaterials. 2017;135:62–73. [DOI] [PubMed] [PMC]

81.

Wu J, Lanier LL. Natural killer cells and cancer. Cancer Res. 2003;90:127–56.

82.

Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189–220. [DOI] [PubMed]

83.

Hayakawa Y, Smyth MJ. Innate immune recognition and suppression of tumors. 2006;95:293–322. [DOI]

84.

López-Soto A, Gonzalez S, Smyth MJ, Galluzzi LJCc. Control of metastasis by NK cells. Adv Cancer Res. 2017;32:135–54. [DOI]

85.

Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. Cancer Res. 2012;72:5428–9. [DOI] [PubMed]

86.

Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72:1070–80. [DOI] [PubMed] [PMC]

87.

Lorenzo-Herrero S, Lopez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez AP, Vitale M, Gonzalez S. NK Cell-Based Immunotherapy in cancer metastasis. Cancers (Basel). 2018;11:29. [DOI]

88.

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503–10. [DOI] [PubMed]

89.

Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. J Innate Immun. 2011;3:274–9. [DOI] [PubMed] [PMC]

90.

Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329–39. [DOI] [PubMed]

91.

Farcas M, Inngjerdingen M. Natural killer cell-derived extracellular vesicles in cancer therapy. Scand J Immunol. 2020;92:e12938. [DOI] [PubMed]

92.

Zhu L, Kalimuthu S, Oh JM, Gangadaran P, Baek SH, Jeong SY, et al. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials. 2019;190–191:38–50. [DOI]

93.

Wang G, Hu W, Chen H, Shou X, Ye T, Xu Y. Cocktail strategy based on NK cell-derived exosomes and their biomimetic nanoparticles for dual tumor therapy. Cancers (Basel). 2019;1:1560. [DOI]

94.

Zhang D, Zheng Y, Lin Z, Lan S, Zhang X, Zheng A, et al. Artificial engineered natural killer cells combined with antiheat endurance as a powerful strategy for enhancing photothermal-immunotherapy efficiency of solid tumors. Small. 2019;15:e1902636. [DOI] [PubMed]

95.

Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526:118–21. [DOI] [PubMed] [PMC]

96.

Han X, Chen J, Chu J, Liang C, Ma Q, Fan Q, et al. Platelets as platforms for inhibition of tumor recurrence post-physical therapy by delivery of anti-PD-L1 checkpoint antibody. J Control Release. 2019;304:233–41. [DOI] [PubMed]

97.

Zhang X, Wang J, Chen Z, Hu Q, Wang C, Yan J, et al. Engineering PD-1-presenting platelets for cancer immunotherapy. Nano Lett. 2018;18:5716–25. [DOI] [PubMed]

98.

Wang C, Sun W, Ye Y, Hu Q, Bomba HN, Gu Z. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nature Biomedical Engineering. 2017;1:0011. [DOI]

99.

Hass R, Kasper C, Böhm S, Jacobs RJCC, Signaling. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12. [DOI] [PubMed] [PMC]

100.

Almalki SG, Agrawal DK. Key transcription factors in the differentiation of mesenchymal stem cells. Differentiation. 2016;92:41–51. [DOI] [PubMed] [PMC]

101.

Jorgensen C, Djouad F, Apparailly F, Noel D. Engineering mesenchymal stem cells for immunotherapy. Gene Ther. 2003;10:928–31. [DOI] [PubMed]

102.

Lu JH, Peng BY, Chang CC, Dubey N, Lo WC, Cheng HC, et al. Tumor-targeted immunotherapy by using primary adipose-derived stem cells and an antigen-specific protein vaccine. Cancers (Basel). 2018;10:446. [DOI]

103.

Almeida-Porada G, Atala AJ, Porada CD. Therapeutic mesenchymal stromal cells for immunotherapy and for gene and drug delivery. Mol Ther Methods Clin Dev. 2020;16:204–24. [DOI] [PubMed] [PMC]

104.

Chen D, Tang P, Liu L, Wang F, Xing H, Sun L, et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway. Cell Cycle. 2018;17:858–67. [DOI] [PubMed] [PMC]

105.

Najar M, Bouhtit F, Melki R, Afif H, Hamal A, Fahmi H, et al. Mesenchymal stromal cell-based therapy: new perspectives and challenges. J Clin Med. 2019;8:626. [DOI]

106.

Rani S, Ryan AE, Griffin MD, Ritter T. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther. 2015;23:812–23. [DOI] [PubMed] [PMC]

107.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. [DOI] [PubMed] [PMC]

108.

Lai P, Weng J, Guo L, Chen X, Du X. Novel insights into MSC-EVs therapy for immune diseases. Biomark Res. 2019;7:6. [DOI] [PubMed] [PMC]

109.

Stephen J, Bravo EL, Colligan D, Fraser AR, Petrik J, Campbell JD. Mesenchymal stromal cells as multifunctional cellular therapeutics - a potential role for extracellular vesicles. Transfus Apher Sci. 2016;55:62–9. [DOI] [PubMed]

110.

Del Fattore A, Luciano R, Pascucci L, Goffredo BM, Giorda E, Scapaticci M, et al. Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes. Cell Transplant. 2015;24:2615–27. [DOI] [PubMed]

111.

Mardpour S, Hamidieh AA, Taleahmad S, Sharifzad F, Taghikhani A, Baharvand H. Interaction between mesenchymal stromal cell-derived extracellular vesicles and immune cells by distinct protein content. J Cell Physiol. 2019;234:8249–58. [DOI] [PubMed]

112.

Bruno S, Collino F, Iavello A, Camussi G. Effects of mesenchymal stromal cell-derived extracellular vesicles on tumor growth. Front Immunol. 2014;5:382. [DOI] [PubMed] [PMC]

113.

Pascucci L, Cocce V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014;192:262–70. [DOI] [PubMed]

114.

Zhang K, Meng X, Yang Z, Cao Y, Cheng Y, Wang D, et al. Cancer cell membrane camouflaged nanoprobe for catalytic ratiometric photoacoustic imaging of microRNA in living mice. Adv Mater. 2019;31:e1807888. [DOI] [PubMed]

115.

Jiang Y, Krishnan N, Zhou J, Chekuri S, Wei X, Kroll AV, et al. Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity. Adv Mater. 2020;32:e2001808. [DOI] [PubMed] [PMC]

116.

Zhen X, Cheng P, Pu K. Recent sdvances in cell membrane-camouflaged nanoparticles for cancer phototherapy. Small. 2019;15:e1804105. [DOI] [PubMed]

117.

Lu Y, Dai J, Kong N, Liu J, Gong J, Yao Y. Internalization characterization of si nanorod with camouflaged cell membrane proteins reveals ATXN2 as a negative regulator. Cells. 2019;8:931. [DOI]

118.

Zhang L, Zhang X, Lu G, Li F, Bao W, Song C, et al. Cell membrane camouflaged hydrophobic drug nanoflake sandwiched with photosensitizer for orchestration of chemo-photothermal combination therapy. Small. 2019;15:e1902648. [DOI] [PubMed]

119.

Yamada N, Kuranaga Y, Kumazaki M, Shinohara H, Taniguchi K, Akao Y. Colorectal cancer cell-derived extracellular vesicles induce phenotypic alteration of T cells into tumor-growth supporting cells with transforming growth factor-β1 mediated suppression. Oncotarget. 2016;7:27033–43. [DOI] [PubMed] [PMC]

120.

Zhao J, Schlosser HA, Wang Z, Qin J, Li J, Popp F, et al. Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers (Basel). 2019;11:874. [DOI]

121.

Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z, et al. Me8lanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 2019;79:4715–28. [DOI] [PubMed]

122.

Horrevorts SK, Stolk DA, van de Ven R, Hulst M, van Het Hof B, Duinkerken S, et al. Glycan-modified apoptotic melanoma-derived extracellular vesicles as antigen source for anti-tumor vaccination. Cancers (Basel). 2019;11:1266. [DOI]

123.

Felgner S, Kocijancic D, Frahm M, Weiss S. Bacteria in cancer therapy: renaissance of an old concept. Int J Microbiol. 2016;2016:8451728. [DOI] [PubMed] [PMC]

124.

Zhou S, Gravekamp C, Bermudes D, Liu K. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18:727–43. [DOI] [PubMed] [PMC]

125.

Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. 2005;102:755–60. [DOI]

126.

Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020;11:2739. [DOI] [PubMed] [PMC]

127.

Gurbatri CR, Lia I, Vincent R, Coker C, Castro S, Treuting PM, et al. Engineered probiotics forlocal tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020;12:eaax0876. [DOI] [PubMed] [PMC]

128.

Liu L, Wu J, Gao J, Lu X. Bacteria-derived nanoparticles: multifunctional containers for diagnostic and therapeutic applications. Adv Healthc Mater. 2020;9:e2000893. [DOI] [PubMed]

129.

Yan S, Luo Z, Li Z, Wang Y, Tao J, Gong C, et al. Improving cancer immunotherapy outcomes using biomaterials. Angew Chem Int Ed Engl. 2020;[Epub ahead of print]. [DOI]

130.

Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019;25:1057–63. [DOI] [PubMed] [PMC]

131.

Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Med. 2019;8:3167–81. [DOI] [PubMed] [PMC]

132.

Yi X, Zhou H, Chao Y, Xiong S, Zhong J, Chai Z, et al. Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer. Sci Adv. 2020;6:eaba3546. [DOI] [PubMed] [PMC]

133.

Xu C, Zhu W, Mao H, Zhang W, Yin GQ, Zhang XE, et al. Switch from polymorphic to homogenous self-assembly of virus-like particles of simian virus 40 through double-cysteine substitution. Small. 2020;16:e2004484. [DOI] [PubMed]

134.

Chen CY, Hutzen B, Wedekind MF, Cripe TP. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother. 2018;7:65–77. [DOI] [PubMed] [PMC]

135.

LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7:35. [DOI] [PubMed] [PMC]

136.

Kerstetter-Fogle A, Shukla S, Wang C, Beiss V, Harris PLR, Sloan AE, et al. Plant virus-like particle in situ vaccine for intracranial glioma immunotherapy. Cancers (Basel). 2019;11:515. [DOI]

137.

Zhang P, Chen Y, Zeng Y, Shen C, Li R, Guo Z, et al. Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc Natl Acad Sci U S A. 2015;112:E6129–38. [DOI] [PubMed] [PMC]

138.

Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, et al. Increased proportion of FoxP3⁺ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. 2015;64:419–27. [DOI] [PubMed] [PMC]

139.

Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell. 2017;32:253–67.e5. [DOI] [PubMed] [PMC]

140.

Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017;77:3894–907. [DOI] [PubMed] [PMC]

141.

Lebel ME, Chartrand K, Tarrab E, Savard P, Leclerc D, Lamarre A. Potentiating cancer immunotherapy using papaya mosaic virus-derived nanoparticles. Nano Lett. 2016;16:1826–32. [DOI] [PubMed]

142.

Martikainen M, Essand M. Virus-based immunotherapy of glioblastoma. Cancers (Basel). 2019;11:186. [DOI]

143.

Parodi A, Molinaro R, Sushnitha M, Evangelopoulos M, Martinez JO, Arrighetti N, et al. Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials. 2017;147:155–68. [DOI] [PubMed]

144.

Jin JW, Tang SQ, Rong MZ, Zhang MQ. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses. Acta Biomater. 2018;78:211–23. [DOI] [PubMed]

145.

Tsoni SV, Brown GD. beta-Glucans and dectin-1. Ann N Y Acad Sci. 2008;1143:45–60. [DOI] [PubMed]

146.

Sahasrabudhe NM, Tian L, van den Berg M, Bruggeman G, Bruininx E, Schols HA, et al. Endo-glucanase digestion of oat β-Glucan enhances Dectin-1 activation in human dendritic cells. J Funct Foods. 2016;21:104–12. [DOI]

147.

Zhang M, Chun L, Sandoval V, Graor H, Myers J, Nthale J, et al. Systemic administration of β-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancer. Oncoimmunology. 2018;7:e1387347. [DOI] [PubMed] [PMC]

148.

Yang Z, Xu M, Jia Z, Zhang Y, Wang L, Zhang H, et al. A novel antigen delivery system induces strong humoral and CTL immune responses. Biomaterials. 2017;134:51–63. [DOI] [PubMed]

149.

Liu H, Jia Z, Yang C, Song M, Jing Z, Zhao Y, et al. Aluminum hydroxide colloid vaccine encapsulated in yeast shells with enhanced humoral and cellular immune responses. Biomaterials. 2018;167:32–43. [DOI] [PubMed]

150.

Wiklander OP, Brennan MLÁ, Lötvall J, Breakefield XO, Andaloussi SE. Advances in therapeutic applications of extracellular vesicles. Sci Transl Med. 2019;11:eaav8521. [DOI] [PubMed] [PMC]

151.

Bosch M, Sanchez-Alvarez M, Fajardo A, Kapetanovic R, Steiner B, Dutra F, et al. Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense. Science. 2020;370:eaay8085. [DOI] [PubMed]

152.

Zhang M, Viennois E, Xu C, Merlin D. Plant derived edible nanoparticles as a new therapeutic approach against diseases. Tissue Barriers. 2016;4:e1134415. [DOI] [PubMed] [PMC]

153.

Yang C, Zhang M, Merlin D. Advances in plant-derived edible nanoparticle-based lipid nano-drug delivery systems as therapeutic nanomedicines. J Mater Chem B. 2018;6:1312–21. [DOI] [PubMed] [PMC]

154.

Zhuang X, Deng ZB, Mu J, Zhang L, Yan J, Miller D, et al. Ginger-derived nanoparticles protect against alcohol-induced liver damage. J Extracell Vesicles. 2015;4:28713. [DOI] [PubMed] [PMC]

155.

Veerman RE, Gucluler Akpinar G, Eldh M, Gabrielsson S. Immune cell-derived extracellular vesicles-functions and therapeutic applications. Trends Mol Med. 2019;25:382–94. [DOI] [PubMed]

156.

Banz A, Cremel M, Rembert A, Godfrin Y. In situ targeting of dendritic cells by antigen-loaded red blood cells: a novel approach to cancer immunotherapy. Vaccine. 2010;28:2965–72. [DOI] [PubMed]